Gilead Sciences (GILD) Long-Term Debt Repayments (2009 - 2026)
Gilead Sciences posted quarterly Long-Term Debt Repayments of $2.8 billion for Q1 2026, up 56.98% year-on-year from $1.8 billion in Q1 2025, and up 34475.0% on a QoQ basis from $8.0 million in Q4 2025.
Gilead Sciences (GILD) has 18 years of Long-Term Debt Repayments data on file, last reported at $2.8 billion in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Debt Repayments rose 56.98% year-over-year to $2.8 billion; the trailing twelve-month figure through Mar 2026 stood at $2.8 billion (down 25.19% YoY), and the FY2025 full-year result was $1.8 billion, down 9.24% from the prior year.
- Long-Term Debt Repayments for Q1 2026 stood at $2.8 billion, up from $8.0 million in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $2.8 billion in Q1 2026 and bottomed at $7.0 million in Q4 2024.
- The 5-year median for Long-Term Debt Repayments is $500.0 million (2022), against an average of $934.0 million.
- The widest annual swing landed in 2023, when Long-Term Debt Repayments soared 125.0%; it then tumbled 99.51% in 2025.
- A 5-year view of Long-Term Debt Repayments shows it stood at $1.0 billion in 2022, then jumped by 125.0% to $2.2 billion in 2023, then plunged by 99.69% to $7.0 million in 2024, then rose by 14.29% to $8.0 million in 2025, then surged by 34475.0% to $2.8 billion in 2026.
- The last three Long-Term Debt Repayments figures came in at $2.8 billion (Q1 2026), $8.0 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 750.00 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 1.14 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 833.00 Mn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.77 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 500.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.77 Bn |
| Mar 31, 2026 | 2.77 Bn |
| Dec 31, 2025 | 8.00 Mn |
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 9.00 Mn |
| Mar 31, 2025 | 1.76 Bn |
| Mar 31, 2025 | 1.76 Bn |
| Dec 31, 2024 | 7.00 Mn |
| Dec 31, 2024 | 7.00 Mn |
| Sep 30, 2024 | 112.00 Mn |
| Sep 30, 2024 | 112.00 Mn |
| Jun 30, 2024 | 1.85 Bn |
| Jun 30, 2024 | 1.85 Bn |
| Sep 30, 2023 | 2.25 Bn |
| Sep 30, 2023 | 2.25 Bn |
| Sep 30, 2022 | 1.00 Bn |
| Sep 30, 2022 | 1.00 Bn |
| Mar 31, 2022 | 500.00 Mn |
| Mar 31, 2022 | 500.00 Mn |
| Dec 31, 2021 | 1.00 Bn |
| Dec 31, 2021 | 1.00 Bn |
| Sep 30, 2021 | 2.50 Bn |
| Sep 30, 2021 | 2.50 Bn |
| Mar 31, 2021 | 1.25 Bn |
| Mar 31, 2021 | 1.25 Bn |
| Sep 30, 2020 | 2.00 Bn |
| Sep 30, 2020 | 2.00 Bn |
| Mar 31, 2020 | 500.00 Mn |
| Mar 31, 2020 | 500.00 Mn |
| Sep 30, 2019 | 1.50 Bn |
| Sep 30, 2019 | 1.50 Bn |
| Jun 30, 2019 | 500.00 Mn |
| Jun 30, 2019 | 500.00 Mn |
| Mar 31, 2019 | 750.00 Mn |
| Mar 31, 2019 | 750.00 Mn |
| Sep 30, 2018 | 1.75 Bn |
| Sep 30, 2018 | 1.75 Bn |
| Mar 31, 2018 | 4.50 Bn |
| Mar 31, 2018 | 4.50 Bn |
| Dec 31, 2017 | 1.72 Bn |
| Dec 31, 2017 | 1.72 Bn |
| Sep 30, 2017 | 30.00 Mn |
| Sep 30, 2017 | 30.00 Mn |
| Jun 30, 2017 | 30.00 Mn |
| Jun 30, 2017 | 30.00 Mn |
| Mar 31, 2017 | 30.00 Mn |
| Mar 31, 2017 | 30.00 Mn |
| Dec 31, 2016 | 730.00 Mn |
| Dec 31, 2016 | 730.00 Mn |
| Sep 30, 2016 | 5.00 Mn |
| Sep 30, 2016 | 5.00 Mn |
| Jun 30, 2016 | 1.12 Bn |
| Jun 30, 2016 | 1.12 Bn |
| Mar 31, 2016 | 126.00 Mn |
| Mar 31, 2016 | 126.00 Mn |
| Dec 31, 2015 | 234.00 Mn |
| Dec 31, 2015 | 234.00 Mn |
| Sep 30, 2015 | 113.00 Mn |
| Sep 30, 2015 | 113.00 Mn |
| Jun 30, 2015 | 451.00 Mn |
| Jun 30, 2015 | 451.00 Mn |
| Mar 31, 2015 | 199.00 Mn |
| Mar 31, 2015 | 199.00 Mn |
| Dec 31, 2014 | 1.92 Bn |
| Dec 31, 2014 | 1.92 Bn |
| Sep 30, 2014 | 421.00 Mn |
| Sep 30, 2014 | 421.00 Mn |
| Jun 30, 2014 | 1.02 Bn |
| Jun 30, 2014 | 1.02 Bn |
| Mar 31, 2014 | 1.42 Bn |
| Mar 31, 2014 | 1.42 Bn |
| Dec 31, 2013 | 2.22 Bn |
| Dec 31, 2013 | 2.22 Bn |
| Sep 30, 2013 | 89.21 Mn |
| Sep 30, 2013 | 89.21 Mn |
| Jun 30, 2013 | 1.79 Bn |
| Jun 30, 2013 | 1.79 Bn |
| Mar 31, 2013 | 347.92 Mn |
| Mar 31, 2013 | 347.92 Mn |
| Dec 31, 2012 | 789.00 Mn |
| Dec 31, 2012 | 789.00 Mn |
| Sep 30, 2012 | 350.00 Mn |
| Sep 30, 2012 | 350.00 Mn |
| Jun 30, 2012 | 699.39 Mn |
| Jun 30, 2012 | 699.39 Mn |
| Mar 31, 2012 | 612,000.00 |
| Mar 31, 2012 | 612,000.00 |
| Dec 31, 2011 | 686.14 Mn |
| Dec 31, 2011 | 686.14 Mn |
| Sep 30, 2011 | -649.99 Mn |
| Sep 30, 2011 | -649.99 Mn |
| Jun 30, 2011 | 648.45 Mn |
| Jun 30, 2011 | 648.45 Mn |
| Mar 31, 2011 | 1.53 Mn |
| Mar 31, 2011 | 1.53 Mn |
| Dec 31, 2010 | 197,000.00 |
| Dec 31, 2010 | 197,000.00 |
| Sep 30, 2010 | 33,000.00 |
| Sep 30, 2010 | 33,000.00 |
| Jun 30, 2010 | 5.54 Mn |
| Jun 30, 2010 | 5.54 Mn |
| Mar 31, 2010 | 19,000.00 |
| Mar 31, 2010 | 19,000.00 |
| Dec 31, 2009 | 49,000.00 |
| Dec 31, 2009 | 49,000.00 |
| Sep 30, 2009 | 305.33 Mn |
| Sep 30, 2009 | 305.33 Mn |
| Jun 30, 2009 | 44,000.00 |
| Jun 30, 2009 | 44,000.00 |
| Mar 31, 2009 | 36,000.00 |
| Mar 31, 2009 | 36,000.00 |